4-phenylbutylamine has been researched along with Osteoarthritis, Knee in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, X; Cai, D; Fang, H; Liu, X; Ouyang, J; Pan, J; Sun, Q; Wang, H; Xie, D; Yan, B; Yang, J; Zeng, C; Zhang, H; Zhang, T; Zhao, C | 1 |
1 other study(ies) available for 4-phenylbutylamine and Osteoarthritis, Knee
| Article | Year |
|---|---|
mTORC1 activation downregulates FGFR3 and PTH/PTHrP receptor in articular chondrocytes to initiate osteoarthritis.
Topics: Adult; Aged; Animals; Butylamines; Cartilage, Articular; Cell Proliferation; Chondrocytes; Down-Regulation; Female; Humans; Hypertrophy; Immunosuppressive Agents; Knee Joint; Male; Mechanistic Target of Rapamycin Complex 1; Menisci, Tibial; Mice; Mice, Knockout; Middle Aged; Osteoarthritis; Osteoarthritis, Knee; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Parathyroid Hormone, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sirolimus; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins; Young Adult | 2017 |